Torigen adds second veterinary oncologist to team of industry experts in continued effort to bring affordable and accessible cancer treatments to the veterinary industry
FARMINGTON, CONN. (PRWEB) OCTOBER 05, 2021
Continuing its momentum to become the industry leader in veterinary biologics, Torigen Pharmaceuticals Inc., today announced that the company has added Dr. Chelsea Greenberg, MS, DVM, DACVIM(O), a veterinary oncologist from Salt Lake City, Utah as its Vice President of Clinical Affairs.
Dr. Greenberg has been a veterinary oncologist for more than 15 years and a veterinary oncology teleconsultant for over 12 years. She joins Torigen as the Vice President of Clinical Affairs, working alongside veterinary hospitals and assisting with clinical trials to advance new cancer therapeutics into the market.
Prior to joining Torigen, Dr. Greenberg was most recently medical director and clinical oncologist for BluePearl Salt Lake City and BluePearl Regional Vice President of Medicine for multiple specialty/ER hospitals in Arizona, California, Nevada, Utah, and Washington state.
Read the full news release here>>